"Ninlaro (Ixazomib) Approved By FDA For Multiple Myeloma", The Myeloma Beacon, Nov 22, 2015
The article includes information on the pricing of Ninlaro. In addition, a representative of Takeda Oncology has provided us with the following statement about Ninlaro's cost:
Each NINLARO 28-day cycle of treatment is list priced at $8,670, which is similar to the monthly cost of Velcade. Velcade has consistently been viewed by independent bodies – such as ASCO, Memorial Sloan Kettering Cancer Center and the NCCN – as a drug with great value. We aspire to continue this value proposition with NINLARO. In fact, NINLARO brings significant innovation to patients, transforming the patient experience and value proposition of proteasome inhibition therapy. So while we are confident in the value NINLARO brings, we have not priced the drug at a premium. This reflects the values of Takeda and our commitment to the multiple myeloma community. It will be available in the first half of December.
Takeda, as you may recall, is the company that developed Ninlaro and will market it globally.
